1090 related articles for article (PubMed ID: 27116120)
21. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.
Fillmore CM; Xu C; Desai PT; Berry JM; Rowbotham SP; Lin YJ; Zhang H; Marquez VE; Hammerman PS; Wong KK; Kim CF
Nature; 2015 Apr; 520(7546):239-42. PubMed ID: 25629630
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
[TBL] [Abstract][Full Text] [Related]
23. Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC.
Piao J; Chen L; Quan T; Li L; Quan C; Piao Y; Jin T; Lin Z
Oncotarget; 2016 Sep; 7(37):60169-60180. PubMed ID: 27507059
[TBL] [Abstract][Full Text] [Related]
24. KiSS-1 Modulation by Epigenetic Agents Improves the Cisplatin Sensitivity of Lung Cancer Cells.
Beretta GL; Alampi D; Corno C; Carenini N; Corna E; Perego P
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732265
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells.
Mateen S; Raina K; Jain AK; Agarwal C; Chan D; Agarwal R
Epigenetics; 2012 Oct; 7(10):1161-72. PubMed ID: 22965008
[TBL] [Abstract][Full Text] [Related]
26. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
Tang YA; Wen WL; Chang JW; Wei TT; Tan YH; Salunke S; Chen CT; Chen CS; Wang YC
PLoS One; 2010 Sep; 5(9):e12417. PubMed ID: 20856855
[TBL] [Abstract][Full Text] [Related]
27. Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines.
Hanke NT; Garland LL; Baker AF
J Cancer Res Clin Oncol; 2016 Mar; 142(3):549-60. PubMed ID: 26385374
[TBL] [Abstract][Full Text] [Related]
28. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
[TBL] [Abstract][Full Text] [Related]
29. Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer.
Quan C; Chen Y; Wang X; Yang D; Wang Q; Huang Y; Petersen RB; Liu X; Zheng L; Li Y; Huang K
Cancer Lett; 2020 Dec; 495():41-52. PubMed ID: 32920200
[TBL] [Abstract][Full Text] [Related]
30. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
Nakagawa T; Takeuchi S; Yamada T; Ebi H; Sano T; Nanjo S; Ishikawa D; Sato M; Hasegawa Y; Sekido Y; Yano S
Cancer Res; 2013 Apr; 73(8):2428-34. PubMed ID: 23382048
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid.
Greve G; Schiffmann I; Lübbert M
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2171-80. PubMed ID: 26008188
[TBL] [Abstract][Full Text] [Related]
32. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
You BR; Han BR; Park WH
Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
[TBL] [Abstract][Full Text] [Related]
33. Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway.
Wang L; Dong X; Ren Y; Luo J; Liu P; Su D; Yang X
Cell Death Dis; 2018 Jan; 9(2):129. PubMed ID: 29374157
[TBL] [Abstract][Full Text] [Related]
34. Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia.
Sun X; Hasanali ZS; Chen A; Zhang D; Liu X; Wang HG; Feith DJ; Loughran TP; Xu K
Br J Haematol; 2015 Feb; 168(3):371-83. PubMed ID: 25284154
[TBL] [Abstract][Full Text] [Related]
35. A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer.
Shieh JM; Tang YA; Hu FH; Huang WJ; Wang YJ; Jen J; Liao SY; Lu YH; Yeh YL; Wang TW; Lin P; Wang YC
Int J Cancer; 2017 May; 140(10):2375-2386. PubMed ID: 28233309
[TBL] [Abstract][Full Text] [Related]
36. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
Leone A; Roca MS; Ciardiello C; Terranova-Barberio M; Vitagliano C; Ciliberto G; Mancini R; Di Gennaro E; Bruzzese F; Budillon A
Free Radic Biol Med; 2015 Dec; 89():287-99. PubMed ID: 26409771
[TBL] [Abstract][Full Text] [Related]
37. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells.
Sun F; Chan E; Wu Z; Yang X; Marquez VE; Yu Q
Mol Cancer Ther; 2009 Dec; 8(12):3191-202. PubMed ID: 19934278
[TBL] [Abstract][Full Text] [Related]
38. Suberoylanilide hydroxamic acid overcomes erlotinib-acquired resistance via phosphatase and tensin homolog deleted on chromosome 10-mediated apoptosis in non-small cell lung cancer.
Wu PF; Gao WW; Sun CL; Ma T; Hao JQ
Chin Med J (Engl); 2020 Jun; 133(11):1304-1311. PubMed ID: 32452893
[TBL] [Abstract][Full Text] [Related]
39. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition.
Hayden A; Johnson PW; Packham G; Crabb SJ
Breast Cancer Res Treat; 2011 May; 127(1):109-19. PubMed ID: 20556507
[TBL] [Abstract][Full Text] [Related]
40. Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.
Takeshima H; Wakabayashi M; Hattori N; Yamashita S; Ushijima T
Carcinogenesis; 2015 Feb; 36(2):192-201. PubMed ID: 25477340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]